A large population-based cohort, treated before the use of trastuzumab, had already shown that OS in breast cancer was not significantly different according to the level of HER-2 amplification, for patients with a HER-2/CEP17 ratio >2.2 (Jensen et al, 2008). Here, ERBB2 is linked to breast cancer.